Download our free ebook: your guide to CRPS filled with incredible knowledge on the condition

CRPS Treatment: pain in leg for 9 months

General details and patient's info

Gender:Female.
Age:48 years old at the time treatment.
Home Country:United States of America.
Illness duration:9 months prior to the Neridronate Treatment.
Cause:Right hip surgery.
Symptoms:Pain triggered by long periods of sitting, standing, walking, exercising. Right lower leg bright, mottled, swollen. Tingling and burning sensation. Cannot tolerate touch or pression, movement is limited and need crutches.
Clinical evaluation:CRPS diagnosis. CRPS in right lower extremity secondary to a right hip labral repair surgery.
Time of treatment:May 2019.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient heard about Neridronate treatment for CRPS on an episode of “House Hunters International” about a previous MTI patient from USA.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330
4 Pantoprazole infusions; Paracetamol;

2 sessions, 2 hours each, of Neuromuscular Rehabilitation Treatment with the Osteopath and Physiotherapist.
Rehabilitation therapy is a full body workout which focuses on the general wellbeing of the body, to help the affected limb get back to its normal self.

Daily Report

DAY 1: Arrival at the Venice airport, greeted by her Patient Manager, followed by check-in at the Hotel in Vicenza. Briefing focused on next days.

DAY 2-3: Rest day, in touch with Patient Manager.

DAY 4: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor, 1st Rehabilitation session, 1st Neridronate infusion.

DAY 5: Morning pick-up by her Patient Manager, 2nd Neridronate infusion. Visit of Verona.

DAY 6: Morning pick-up by her Patient Manager, 3rd Neridronate infusion. Visit of Garda Lake and Sirmione.

DAY 7: Morning pick-up by her Patient Manager, 2nd with Rheumatologist Professor, last Neridronate infusion.

DAY 8: Morning pick-up by her Patient Manager, 2nd rehabilitation session.

DAY 9: Morning pick-up by her Patient Manager and day trip to Venice.

DAY 10: Rest day, in touch with Patient Manager.

DAY 11: Morning pick-up by her Patient Manager, check-out at the hotel, and drop-off Venice airport.

Follow up

AUGUST 2019 (3 month after treatment): the patient is very happy: she has no more discoloration in her leg. She is positive about further improvements.

DECEMBER 2019 (7 months after treatment): the patients refers big improvements both on sensitivity and pain and she is going back to her activities. She now walks without crutches.

DECEMBER 2022 (3 years and half after treatment): the patient is in full remission, she sends videos of her dancing and running marathon.

Conclusion

This is a very successful case. The patient tolerated very easily the Neridronate infusions, she had no side effects while she was in Italy. There was a long follow up with her and her MTI Patient Manager still keeps in touch with her, as it often happens.
4 years after the treatment the woman is still in a lasting full remission.

DISCLAIMER
This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.